Zyprexa patent litigation
Executive Summary
Lilly expects "a trial date to be scheduled for the fourth quarter of 2003" for consolidated patent litigation related to its antipsychotic Zyprexa, company says in second quarter 10-Q filing with Securities & Exchange Commission. Lilly filed an infringement suit against Zenith in Indianapolis federal court last year over an olanzapine patent set to expire in 2011; Ivax was "first to file" an ANDA for olanzapine in February 2001 (1"The Pink Sheet" Feb. 26, 2001, p. 32). Lilly was notified that Dr. Reddy's also filed an ANDA covering additional dosage forms of olanzapine in May 2001 and January 2002. "In February 2002, we filed an infringement suit in the same court based on Reddy's later ANDA. The Zenith and Reddy cases have been consolidated and are in the discovery stage," Lilly says...
You may also be interested in...
Lilly Zyprexa
Ivax is "first to file" an ANDA for generic olanzapine. The compound patent has protection through 2011, Lilly says. The application follows trend for companies to file after a product's four-year Waxman/Hatch prohibition on ANDA filings expires, Lilly says
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.